Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
Steven A Nielsen,1 Marguerite B McDonald,2 Parag A Majmudar31Nielsen Eye Center, Quincy, MA, USA; 2Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 3Chicago Cornea Consultants Hoffman Estates, IL, USABackground: To evaluate the safety of besifloxacin ophthalmic suspension 0.6% when used in...
Guardado en:
Autores principales: | Nielsen SA, McDonald MB, Majmudar PA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d6b4bbe8a6784bbd8e8d01cbb62b490b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen SA, et al.
Publicado: (2013) -
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein BE, et al.
Publicado: (2012) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris TW, et al.
Publicado: (2011) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas W, et al.
Publicado: (2011) -
Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau JM, et al.
Publicado: (2021)